Bristol Myers' KarXT Shows Positive Phase 3 Data in Schizophrenia Treatment
Monday, 8 April 2024, 15:38
Bristol Myers Unveils Promising Phase 3 Data for Schizophrenia Drug
Bristol Myers (BMY) has shared positive interim results from a Phase 3 clinical study of KarXT, a drug designed for schizophrenia treatment. The findings point towards encouraging developments in the field of mental health.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.